Arteriovenous Malformations Market on Track for Major Expansion by 2032, According to DelveInsight | Genentech, Micro Therapeutics Inc., Shire, Eisai Co., Ltd., Merck Sharp & Dohme LLC, Proteon

June 25 16:55 2024
Arteriovenous Malformations Market on Track for Major Expansion by 2032, According to DelveInsight | Genentech, Micro Therapeutics Inc., Shire, Eisai Co., Ltd., Merck Sharp & Dohme LLC, Proteon
The Arteriovenous Malformations Market Forecast report offers an in-depth understanding of the Arteriovenous Malformations, historical and forecasted epidemiology as well as the Arteriovenous Malformations market trends in the 7MM.

DelveInsight’s “Arteriovenous Malformations Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Arteriovenous Malformations, historical and forecasted epidemiology as well as the Arteriovenous Malformations market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Arteriovenous Malformations market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Arteriovenous Malformations Market Forecast

 

Some of the key facts of the Arteriovenous Malformations Market Report: 

  • The Arteriovenous Malformations market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • Brain Arteriovenous Malformations are believed to be present in less than 1% of the overall population. In the 7MM countries, approximately 1 in 2000 individuals are affected by the prevalence of AVMs.

  • While Arteriovenous Malformations can manifest in various parts of the body, they predominantly occur in the brain and spine. Studies indicate that 1 out of every 100 Arteriovenous Malformations patients experiences a stroke annually.

  • The most accurate projections for identifying a new Arteriovenous Malformations case are approximately 1 per 100,000 individuals annually, equating to around 3000 new cases detected each year in the U.S. The overall population prevalence stands at approximately 10 per 100,000, suggesting that there are likely around 30,000 individuals in the U.S. affected by AVMs.

  • Key Arteriovenous Malformations Companies: Genentech, Inc., Micro Therapeutics Inc., Shire, Eisai Co., Ltd., Merck Sharp & Dohme LLC, Proteon Therapeutics, and others

  • Key Arteriovenous Malformations Therapies: Cobimetinib, Onyx, SRM003, E7040, Vorapaxar sulfate, PRT-201, and others

  • The Arteriovenous Malformations market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Arteriovenous Malformations pipeline products will significantly revolutionize the Arteriovenous Malformations market dynamics.

 

Arteriovenous Malformations Overview

Arteriovenous malformations (AVMs) are abnormal, tangled clusters of blood vessels in which arteries connect directly to veins without the normal intervening capillaries. This bypass of the capillary system can lead to a variety of issues due to the high pressure of arterial blood being shunted directly into the veins.

 

Get a Free sample for the Arteriovenous Malformations Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/arteriovenous-malformations-market

 

Arteriovenous Malformations Epidemiology

The epidemiology section offers an in-depth look at the historical, current, and projected epidemiology trends across the seven major countries (7MM) from 2019 to 2032. By examining various studies and expert opinions, it identifies the factors driving present and future trends. This section also includes a comprehensive analysis of the diagnosed patient population and anticipated future patterns.

 

Arteriovenous Malformations Epidemiology Segmentation:

The Arteriovenous Malformations market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Arteriovenous Malformations

  • Prevalent Cases of Arteriovenous Malformations by severity

  • Gender-specific Prevalence of Arteriovenous Malformations

  • Diagnosed Cases of Episodic and Chronic Arteriovenous Malformations

 

Download the report to understand which factors are driving Arteriovenous Malformations epidemiology trends @ Arteriovenous Malformations Epidemiology Forecast

 

Arteriovenous Malformations Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Arteriovenous Malformations market or expected to get launched during the study period. The analysis covers Arteriovenous Malformations market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Arteriovenous Malformations Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Arteriovenous Malformations Therapies and Key Companies

  • Cobimetinib: Genentech, Inc.

  • Onyx: Micro Therapeutics Inc.

  • SRM003: Shire

  • E7040: Eisai Co., Ltd.

  • Vorapaxar sulfate: Merck Sharp & Dohme LLC

  • PRT-201: Proteon Therapeutics

 

Discover more about therapies set to grab major Arteriovenous Malformations market share @ Arteriovenous Malformations Treatment Landscape

 

Scope of the Arteriovenous Malformations Market Report

  • Study Period: 2019–2032

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Arteriovenous Malformations Companies: Genentech, Inc., Micro Therapeutics Inc., Shire, Eisai Co., Ltd., Merck Sharp & Dohme LLC, Proteon Therapeutics, and others

  • Key Arteriovenous Malformations Therapies: Cobimetinib, Onyx, SRM003, E7040, Vorapaxar sulfate, PRT-201, and others

  • Arteriovenous Malformations Therapeutic Assessment: Arteriovenous Malformations current marketed and Arteriovenous Malformations emerging therapies

  • Arteriovenous Malformations Market Dynamics: Arteriovenous Malformations market drivers and Arteriovenous Malformations market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Arteriovenous Malformations Unmet Needs, KOL’s views, Analyst’s views, Arteriovenous Malformations Market Access and Reimbursement 

 

To know more about Arteriovenous Malformations companies working in the treatment market, visit @ Arteriovenous Malformations Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Arteriovenous Malformations Market Report Introduction

2. Executive Summary for Arteriovenous Malformations

3. SWOT analysis of Arteriovenous Malformations

4. Arteriovenous Malformations Patient Share (%) Overview at a Glance

5. Arteriovenous Malformations Market Overview at a Glance

6. Arteriovenous Malformations Disease Background and Overview

7. Arteriovenous Malformations Epidemiology and Patient Population

8. Country-Specific Patient Population of Arteriovenous Malformations 

9. Arteriovenous Malformations Current Treatment and Medical Practices

10. Arteriovenous Malformations Unmet Needs

11. Arteriovenous Malformations Emerging Therapies

12. Arteriovenous Malformations Market Outlook

13. Country-Wise Arteriovenous Malformations Market Analysis (2019–2032)

14. Arteriovenous Malformations Market Access and Reimbursement of Therapies

15. Arteriovenous Malformations Market Drivers

16. Arteriovenous Malformations Market Barriers

17.  Arteriovenous Malformations Appendix

18. Arteriovenous Malformations Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/